Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Statins, a major class of drugs for treatment of hypercholesterolemia, are widely used due to a notable prevention of cardiovascular disease, and accumulating evidence proposes a promising role of statins in breast cancer
Statin has lipid independent effects include inhibition of inflammatory responses, immunomodulatory actions, apoptotic and antiproliferative effects, which might contribute to the suggested anti-tumoral effects of these agents. The epidemiological evidence projecting statins as anticancer agents is variable, depending on the particular type of cancer in question as well as the class of statin used
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| study | Experimental | breast cancer patient received Atorvastatin 80 mg |
|
| control group | Placebo Comparator | breast cancer patient received placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Atorvastatin 80mg | Drug | patients received statin experimental group |
|
| Measure | Description | Time Frame |
|---|---|---|
| Ki-67 molecular | antiproliferative effect Ki-67 molecular gene expression | 3 month |
| TAZ (WWTR1) TAZ expression | cell proliferative ability via TAZ (WWTR1) TAZ expression | 3 months |
| cardiac markers | protective effect of atorvastatin for Anthracycline induced cardiotoxicity | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival OS | The length of time from r the start of treatment for a disease and are still alive | time frame 6 month |
| Overall response rate | the proportion of patients who have a partial or complete response to therapy |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Femal breast cancer
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| ALshaimaa Ibrahim Rabie, Msc | Contact | 01061263030 | alshaimaa.ph@o6u.edu.eg | |
| Raghda RS Hussein, PHD | Contact | Raghda.hussien@phram.bsu.edu.eg |
| Name | Affiliation | Role |
|---|---|---|
| Ahmed Hassan shaaban, MD | Beni-Suef University | Study Director |
| Raghda RS Hussein, PHD | Beni-Suef University | Study Director |
| Reham shehab El-Nemr, MD |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fayoum Oncology Center | Not yet recruiting | Al Fayyum | Egypt |
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069059 | Atorvastatin |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
study group control group
Not provided
Not provided
single blind
| placebo | Other | patients received placebo control group |
|
|
| 6 months |
| Fayoum University |
| Study Director |
| Beni-Suef university hospital | Recruiting | Banī Suwayf | Egypt |
|
| D017437 |
| Skin and Connective Tissue Diseases |
| D006538 |
| Heptanoic Acids |
| D005227 | Fatty Acids |
| D008055 | Lipids |